EN
CH
JP
Effepharm’s UTHEVER® NMN: 66 people Human Clinical Trial Data Published, NAD+/NADH Level increased 38% in 2 months!
by Effepharm | May 17, 2022 | About NMN, Company news
On 5th May 2022, Frontier in Aging, an authoritative international journal on aging mechanisms, published one NMN clinical trial report with new insights and more experience being brought into the...UTHEVER®, NMN’s Modified Advanced Technology by Effepharm- QbD
by Effepharm | July 12, 2021 | About NMN, Company news
On July 9th, Dr. Liu from Effepharm delivered a speech entitled "UTHEVER®, NMN’s Modified Advanced Technology by Effepharm" at HFIC(Healthy China 2021 Nutrition and Health Food Conference), telling the advanced...
Subacute Toxicity of NMN
by Effepharm | February 18, 2021 | About NMN, Company news
The administration of Nicotinamide mononucleotide(NMN) which is a key precursory metabolite of NAD+ has been reported to have remarkable therapeutic effects on age-related diseases. However systemic evaluation pertaining to the...
Hi Mrs, NMN Helps Pregnancy
by Effepharm | February 2, 2021 | About NMN, Company news
With the increasing, late marriage and late childbirth in China, as well as the two-child policy, and even the looming phenomenon of the third child in some regions, the group...
NMN，A Heart Disease Terminator
by Effepharm | January 26, 2021 | About NMN, Company news
As the engine of the human body, the heart occupies an incomparable position in the body. Obligations, however, go hand in hand with responsibilities. The fate of the heart is...
What are the changes NMN can visibly make on you?
by Effepharm | January 19, 2021 | About NMN, Company news
Since the nicotinamide mononucleotide (NMN) was found to promote the increase of NAD+ in the body, the scientific research on its anti-aging effect in an endless stream of studies, and...
NMN Has Anti-Aging Potential for Kidneys
by Effepharm | January 13, 2021 | About NMN, Company news
The world’s population of older adults continues to expand at an unprecedented pace. So, there is a need for a better understanding of aging processes to mitigate age-related diseases and...
How does NMN work in Sirtfood Diet?
by Effepharm | January 6, 2021 | About NMN, Company news
It’s common knowledge that health and longevity go hand in hand with diet, which has encouraged many people to pay close attention to what they eat. Although restricting calorie intake...
Effepharm’s R&D Director got an outstanding achievement award for scientific research
by Effepharm | December 24, 2020 | About NMN, Company news
Effepharm’s R&D Director got an outstanding achievement award for scientific research Dr. Jianjun Yu, Effepharm’s R&D Director, got an outstanding achievement award for scientific research of the ministry of education...
Meet us at CPhi 2020 at Booth E5A08
by Effepharm | December 4, 2020 | About NMN, Company news
From 16Dec to 18Dec 2020, Effepharm will attend CPhi 2020 in Shanghai, China. As an exhibitor, our booth will be E5A08 At the expo, Effepharm will introduce its next-generation NMN...
UTHEVER®NMN AWARDED 2020 TOP 10 HOT RAW MATERIALS IN THE NUTRITION AND HEALTH INDUSTRY
by Effepharm | November 23, 2020 | About NMN, Company news
2020 Nutrition Health Entrepreneur Conference (NHEC) was hosted in Bejing International Conference center on Nov.22nd, 2020. With the theme of “Embracing the Future of change and Win-win,” this annual conference...
Brief comparison between NMN cocktail therapy and mRNA vaccine
by Effepharm | November 19, 2020 | About NMN, Company news
Undoubtedly, the whole world is undergoing great shock under the COVID-19 circumstance. According to some statistics, the number of deaths caused by coVID-19 in the US is equivalent to crushing...
Study revealed that NMN may imparts protection against Doxorubicin-induced cardiotoxicity
by Effepharm | November 11, 2020 | About NMN, Company news
Recently, the WHO and IARC released the latest World Cancer Report, which provides a comprehensive overview of the global burden of increasing cancer-incidence, risk factors, and biological processes of cancer...
Research Shows that NMN May Improve Fertility Quality of Aged-women
by Effepharm | November 4, 2020 | About NMN, Company news
High-quality oocytes, a prerequisite for successful fertilization and subsequent embryonic development, are the material basis for life onset. In most mammals, female senescence processes show an evident decline in follicles...
Effepharm Won the 2020 “NEW POWER” Innovation Award For the NMN Brand Material UTHEVER®
by Effepharm | October 26, 2020 | About NMN, Company news
Asiaceutical Summit & Expo 2020 took place in Guangzhou from October 21st to 23rd. This conference was hosted by the Herbridge, which gathered the experts in foods, beverage and health care...
Meet us at Asiaceutical Summit & Expo 2020
by Effepharm | September 30, 2020 | About NMN, Company news
From 21Oct to 23Oct 2020, Effepharm will attend Asiaceutical Summit & Expo 2020 in Guangdong, China. As an exhibitor, our booth will be B17. At the expo, Effepharm will introduce...
A new PCT patent of Uthever® NMN filed by Effepharm recently
by Effepharm | September 10, 2020 | About NMN, Company news
Effepharm recently filed a new PCT patent of Uthever® NMN . The following is the patent details. The patent is an application of nicotinamide mononucleotide in preparation of reagent for increasing...
Super Stable NMN- The Second Generation of Uthever®
by Effepharm | September 9, 2020 | About NMN, Company news
Living up to expectations, the second-generation of Uthever® NMN article finally come to public！ While NMN is becoming more and more popular in the anti-aging market, with the rampant of fakes,...
Effepharm started new clinical trials on Uthever® NMN
by Effepharm | March 19, 2020 | About NMN, Company news
Effepharm started new clinical trials on Uthever® NMN Effepharm started our new clinical trials on Uthever® NMN ingredient recently. According to ICTRP ( International Clinical Trials Registry Platform), the clinical trial on...
Clinical evidence on the safety of NMN released recently
by Effepharm | March 19, 2020 | About NMN, Company news
Clinical evidence on the safety of NMN released recently Researchers from Keio University and Washington University published a new article on Endocrine Journal. The safety of single dose at 100, 250, and...
Effepharm announced acquisitions and new R&D center establishment
by Effepharm | December 24, 2019 | About NMN, Company news
Effepharm announced acquisitions and new R&D center establishment Effepharm acquired two bio-pharmaceutical companies recently, named Dendrimer Co. and Folvo Co., the acquisition has significantly enhanced our R&D capability in anti-aging...
Branded NMN powder from Effepharm turns an instant hit at SupplySide West 2019
by Effepharm | November 4, 2019 | About NMN, Company news
Branded NMN powder from Effepharm turns an instant hit at SupplySide West 2019 From 15th to 19th, Oct 2019, Effepharm attended the Supplyside West 2019 held in the United States...
Effepharm’s R&D Director got an outstanding achievement award for scientific research
by Effepharm | November 4, 2019 | About NMN, Company news
Effepharm’s R&D Director got an outstanding achievement award for scientific research Dr. Jianjun Yu, Effepharm’s R&D Director, got an outstanding achievement award for scientific research of the ministry of education...
NMN ingredient of Effepharm made its debut at Hi Japan exhibition
by Effepharm | October 9, 2019 | About NMN, Company news
NMN ingredient of Effepharm made its debut at Hi Japan exhibition From 2th to 4th, Oct 2019, Effepharm team participated in Hi Japan Exhibit, the largest trade show for functional...